BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 24440671)

  • 1. Interactions between the intestinal microbiome and liver diseases.
    Schnabl B; Brenner DA
    Gastroenterology; 2014 May; 146(6):1513-24. PubMed ID: 24440671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
    Chen P; Torralba M; Tan J; Embree M; Zengler K; Stärkel P; van Pijkeren JP; DePew J; Loomba R; Ho SB; Bajaj JS; Mutlu EA; Keshavarzian A; Tsukamoto H; Nelson KE; Fouts DE; Schnabl B
    Gastroenterology; 2015 Jan; 148(1):203-214.e16. PubMed ID: 25239591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gut microbiota in liver disease.
    Albhaisi SAM; Bajaj JS; Sanyal AJ
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G84-G98. PubMed ID: 31657225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking intestinal homeostasis and liver disease.
    Schnabl B
    Curr Opin Gastroenterol; 2013 May; 29(3):264-70. PubMed ID: 23493073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-microbiome interactions in alcoholic liver disease.
    Chen P; Schnabl B
    Gut Liver; 2014 May; 8(3):237-41. PubMed ID: 24827618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enteric dysbiosis associated with a mouse model of alcoholic liver disease.
    Yan AW; Fouts DE; Brandl J; Stärkel P; Torralba M; Schott E; Tsukamoto H; Nelson KE; Brenner DA; Schnabl B
    Hepatology; 2011 Jan; 53(1):96-105. PubMed ID: 21254165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
    Wieland A; Frank DN; Harnke B; Bambha K
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.